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Abstract 
Covid-19, a serious respiratory complications caused by SARS-CoV-2 has become one of the global 
threat to human healthcare system. The present study evaluated the possibility of plant originated 
approved 117 therapeutics against the main protease protein (MPP), RNA-dependent RNA 
polymerase (RdRp) and spike protein (S) of SARS-CoV-2 including drug surface analysis by using 
molecular docking through drug repurposing approaches. The molecular interaction study revealed 
that Rifampin (-16.3 kcal/mol) were topmost inhibitor of MPP where Azobechalcone were found most 
potent plant therapeutics for blocking the RdRp (-15.9 kcal /mol) and S (-14.4 kcal/mol) protein of 
SARS-CoV-2. After the comparative analysis of all docking results, Azobechalcone, Rifampin, 
Isolophirachalcone, Tetrandrine and Fangchinoline were exhibited as the most potential inhibitory 
plant compounds for targeting the key proteins of SARS-CoV-2. However, amino acid positions; H41, 
C145, and M165 of MPP played crucial roles for the drug surface interaction where F368, L371, L372, 
A375, W509, L514, Y515 were pivotal for RdRP. In addition, the drug interaction surface of S proteins 
also showed similar patterns with all of its maximum inhibitors. ADME analysis also strengthened the 
possibility of screened plant therapeutics as the potent drug candidates against SARS-C with the 
highest drug friendliness.  
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1. Introduction  
COVID-19 pandemic situation has tremendously turned the entire world into a place of horrible death 
tragedy. SARS-CoV-2, initially named as 2019 novel coronavirus (2019-nCoV) by the World Health 
Organization (WHO) is the causative agent of the recent serious respiratory complications resulting 
the COVID-19 pandemic [1,2,3,4]. Though the symptoms of COVID-19 infection appear after an 
incubation period of approximately 5.2 days, the period from the onset of COVID-19 symptoms to 
death ranged from 6 to 41 days with a median of 14 days [5,6]. It has already completed its world tour, 
and around 213 countries are now experiencing the deadly scene occurred by COVID-19 including 
41, 52,670 infected patients and 2, 84,536 global death cases till 12th May, 2020 [7]. The scientific 
community is racing to explore the effective remedy against this severe health complications, but till 
to date there are no any potential therapeutics have been approved for clinical use [8].  
 
There have been few key proteins of SARS-CoV-2 that could be targeted as the vaccine or drug surface 
[9]. Similar to SARS and MERS, non-structural proteins (e.g. 3-chymotrypsin-like protease 
coronavirus main protease, papain-like protease, helicase, and RNA-dependent RNA polymerase), 
structural proteins (e.g. spike glycoprotein) and accessory proteins were investigated in the genome of 
SARS-CoV-2 where non-structural proteins constitute two-thirds of the entire genome [10]. Among 
the structural proteins, Nucleocapsid (N) protein is prerequisite for RNA genome assembly where 
Membrane (M) and Envelope (E) proteins are associated in viral assembly in the host environment 
[11]. Moreover, Spike (S) protein is mainly responsible for the viral entry into the host cell, and that 
is why spike protein is now being considered as a major therapeutic target for drug and vaccines 
against SARS-CoV-2 [12].  Again, The S protein interaction with the human ACE2 interface has been 
revealed at the atomic level, and the efficiency of ACE2 usage was found to be a main factor of 
coronavirus transmissibility in human to human [13]. On the contrary, coronavirus main protease (M
pro) or 3C-like proteinase (3CLP) was reported for their ability to cleave the polyproteins into 
individual polypeptides that are required for replication and transcription [14]. The 3CLP is auto-
cleaved initially from the polyproteins to become a mature enzyme leading the translation of the 
messenger RNA [15]. Then the 3CLP cleaves all the 11 downstream non-structural proteins. As 3CLP 
plays a vital role in the replication cycle of virus in the host, it has been reported as the attractive target 
against the human SARS virus [16]. RNA-dependent RNA polymerase, other key target protein of 
SARS-CoV-2 catalyses the synthesis of viral RNA possibly with the support of other non-structural 
proteins as co-factors [17,18,19].  
The computational drug repurposing method could allow the immediate search of potential antiviral 
therapy in case of re-emergence of viral infections as like as COVID-19 pandemic situation [20,21,22].  
Computational drug repurposing has already been used to identify promising drug candidates for other 
virus associated diseases like Dengue, Ebola, ZIKA, and influenza infections [23,24]. Most 
importantly, the SARS-CoV-2 has shown evolutionary convergent relations with SARS-CoV and 
MERS-CoV, and the drug repurposing methods were also applied to SARS-CoV and MERS-CoV 
[25,26,27]. Hence, extensive in silico studies were performed to identify potential drug candidates, for 
example, Prulifloxacin, Bictegravir, Nelfinavir, and Tegobuvi, were identified as repurposing 
candidates against COVID-19 by looking for drugs with high binding capacity with SARS-CoV main 
protease [28]. Again, Nelfinavir, an HIV-1 protease inhibitor was also predicted to be a potential 
inhibitor of COVID-19 main protease by another computational-based study [29].  
However, secondary metabolites from plant origin are found to show effective defence mechanism 
against different deadly pathogens, and they have been widely used for conventional remedy to treat 
a wide range of human diseases since the ancient period of human civilization [30,31,32]. In this 
pandemic situation, researchers are trying find out the effective solution against COVID-19 where 
plant metabolites could be a promising wings for screening out potential drug candidates. Even few 
plant secondary metabolites have already been reported as effective against other coronaviruses 
[33,34]. In the present study, a total of 117 plant based drug compound were screened out to check 
their potentiality for blocking the three important key proteins of SARS-CoV-2. The main protease 
proteins, RNA-dependent RNA polymerase and spike protein of SARS-CoV-2 were employed to 
molecular docking study with the repurposed drug candidates from plant origin for find out the better 
drug option towards the COVID-19 pandemic.   
 
2. Materials and Methods 
2.1 Retrieval of SARS-CoV-2 main protease proteins, RNA-dependent RNA polymerase, spike 
protein and acquisition of potential natural therapeutics 
PDB structures of SARS-CoV-2 main protease proteins (6LU7, 6Y2E), RNA-dependent RNA 
polymerase (6M71) and spike protein (6VYB) were retrieved from RCSB Protein Data Bank [35]. 
Moreover, a total 117 plant based drugs were collected from PubChem database (Supplementary Table 
1). Alpha-ketoamide (CID 6482451) were also retrieved from the PubChem database database 
(https://pubchem.ncbi.nlm.nih.gov/) of NCBI [36].  
2.2. Screening of natural therapeutics against the key viral proteins 
Molecular docking is an effective approach for screening out potential therapeutics against specific 
drug-targets of deadly pathogens [37,38]. The crystal structure of retrieved SARS-CoV-2 proteins 
(complexed with inhibitors) were refined by PyMOL v2.0 software [39]. Unwanted molecules i.e. 
water, ions, inhibitors were removed from the viral retrieved viral protein, and further employed to 
molecular docking experiment with 117 natural therapeutics.  AutoDock Vina software [40] to analyse 
the binding affinity and interactive amino acids. Alpha-ketoamide, an inhibitor SARS-CoV-2 main 
protease protein were used as a positive control in this study [41] and also docked against the target 
proteins of SARS-CoV-2. The default parameters for grid box were set to 62 A° x 71 A° x 60 A° (x, 
y and z) and center -25.389 A° x 15.333 A° x 56.865 A° (x, y and z) to perform the action.  Moreover, 
2D ligand-protein interaction diagrams were generated by LigPlot+ find out the involved amino acids 
with their interactive position were identified in the docked complexes [42]. The ligand molecules’ 
interactions with the viral proteins were visualize and analyzed by Discovery Studio [43] and PyMOL 
v2.0 software [44].   
2.3. Structural insights of drug surface hotspot in the viral proteins  
The drug surface hotspot of SARS-CoV-2 proteins were identified by analysing the docked structures 
of each protein with the top most natural therapeutics by LigPlot+, PyMOL v.2.0 and Discovery Studio 
software. Binding patterns of Azobechalcone, Rifampin, Isolophirachalcone, Tetrandrine, 
Fangchinoline with SARS-CoV-2 proteins and the results were allowed for the comparative structural 
analysis of screened natural therapeutics. Furthermore, interactions of Alpha-ketoamide with the 
studied proteins were also investigated. 
2.4. Analysis of drug likeness property of top drug candidates 
The ADME (Absorption, Distribution, Metabolism and Excretion) properties of top drug candidates 
were analysed by SwissADME server [45]. The pharmacokinetics, drug-likeness property and 
medicinal chemistry were assessed [46]. Default parameters were used to evaluate various 
physiochemical parameters (Molar Refractivity, Molecular weight, TPSA), lipophilicity (Log Po/w 
(WLOGP), Log Po/w (MLOGP), Log Po/w (XLOGP3), Log Po/w, (SILICOS-IT), Log Po/w 
(iLOGP), Consensus Log Po/w), pharmacokinetics parameters (Log Kp; skin permeation) and water 
solubility of the probable drug candidates [47]. The inhibition effects of these natural therapeutics with 
different cytochromes P450s (CYP2C9, CYP2C19 CYP1A2, CYP3A4, CYP2D6) were also studied. 
In addition, admetSAR and OSIRIS Property Explorer were employed to evaluate the toxic or 
undesired effects (i.e. mutagenicity, tumerogenecity) of the compounds [48,49,50].  
 
3. Results 
 
3.1. Screening of natural therapeutics against the key viral proteins 
All of the retrieved natural therapeutics were employed for molecular docking against MPP, RdRp 
and Spike protein of SARS-CoV-2 (Supplementary Table 2). The scoring function of AutoDock Vina 
was utilized to predict the interaction between the ligands (therapeutics) and the proteins. The top five 
inhibitors for each protein was identified based on their free binding energy. Results showed that 
Rifampin had the highest negative binding energy (-16.3 kcal/mol) among top MPP inhibitors (Table 
1). Azobechalcone (-14.6 kcal/mol), Isolophirachalcone (-13 kcal/mol), Amentoflavone (-12.8 
kcal/mol) and Cepharanthine (-12.7 kcal/mol) docked with the MPP of SARS-CoV-2 were also 
exhibited topmost place with a higher negative binding energy (<-12.7 kcal/mol) as well (Table 1). 
While interacting with RdRp of SARS-CoV-2, the most negative binding energy was scored by 
Azobechalcone (-15.9 kcal /mol) following by Rifampin (-15.6 kcal/mol), Tetrandrine (-13.9 
kcal/mol), Biflavone (-13.7 kcal/mol), Biflavone (-13.7 kcal/mol) (Table 2). Moreover, 
Azobechalcone, Rifampin, Isolophirachalcone, Fangchinoline and Tetrandrine were found to be top 
most natural inhibitors for the spike protein of SARS-CoV-2. Azobechalcone required lowest energy 
(-14.4 kcal/mol) to interact with the spike protein, while Rifampin, Isolophirachalcone, Fangchinoline 
and Tetrandrine scored -13.7 kcal/mol , -12.8 kcal/mol, -12.6 kcal/mol and -12.5 kcal/mol respectively 
(Table 3). However, Azobechalcone, Rifampin, Isolophirachalcone, Tetrandrine and Fangchinoline 
were found to be most effective inhibitory natural compounds when the docking results were 
compared for all three SARS-CoV-2 proteins (Figure 2 and Table 4). All of these plant based natural 
inhibitors required minimum energy (not more than -12.3 kcal/mol) to interact with the studied protein 
molecules. 
3.2.Structural insights of drug surface hotspot in the viral proteins  
The docking pattern and interacting amino acid residues with their respective position were analyzed 
to unravel the binding sites of studied SARS-CoV-2 proteins. Rifampin were involved with the amino 
acid H41, N142, S144, C145, H163, M165, E166, D187, R188,  Q189 of MPP of SARS-CoV-2 
(Figure 2). The position of H41, C145, and M165 were also crucial for the binding of Amentoflavone 
(H41, C145, H164, M165, E166, D187, R188, Q189) and Cepharanthine (H41, N142, C145, M165, 
E166, D187, R188, Q189) (Table 1). Azobechalcone, the top scorer among RdRp inhibitors, were 
engaged by Y32, K47, L49, Y129, H133, N138, D140, T141, S709, T710, D711, K714, K780, N781 
in the docked complex. Moreover, results revealed that 6 amino acid positions i.e. F368, L371, L372, 
A375, W509, L514, Y515 were crucial for binding pattern of RdRP with Tetrandrine, Biflavone and 
Fangchinoline ( Figure 3 and Table 2). Remarkably, binding patterns of spike protein with 
Isolophirachalcone (R355, Y396, P426, D428, F429, T430, K462, P463, F464, F515), Fangchinoline 
(R355, Y396, P426, N428, P463, F464, S514, F515, E516) and Tetrandrine (R355, Y396, P426, N428,  
P463, F464,  S514, F515, E516) were exactly similar as all 9 amino acid residues i.e. R355, Y396, 
P426, N428,  P463, F464,  S514, F515, E516 were critical for binding with the protein (Figure 4). 
However, an additional residue T430 were involved in case of Isolophirachalcone (Table 3). P426, 
D428, T430, P463, F464 and F515 were also critical for binding pattern of Rifampin and SARS-CoV-
2 spike protein. 
3.3.Analysis of drug likeness property of top drug candidates  
The most potent MPP, RdRp and spike protein inhibitors (Azobechalcone, Rifampin, 
Isolophirachalcone, Tetrandrine and Fangchinoline) were investigated in the spheres of 
physicochemical parameters, lipophilicity, pharmacokinetics and water solubility (Table 5). 
Lipophilicity, partition coefficient between n-octanol and water (log Po/w) were also calculated by 
using five widely available predictive models (XLOGP3, WLOGP, MLOGP, SILICOS-IT, iLOGP). 
GI absorption was lower for all the drug candidates. Azobechalcone, Rifampin, Isolophirachalcone, 
Tetrandrine and Fangchinoline molecules had no repressive action with the P450 (CYP) isoforms 
(CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4). Moreover, no permeant BBB exists among the 
protein inhibitors of MPP, RdRp and Spike. The compounds sowed water solubility from moderate to 
high level i.e. 1.30e-16 mg/ml, 1.50e-02 mg/ml, 1.18e-10 mg/ml, 9.78e 09 mg/ml, 4.61e-08 mg/ml, 
respectively (Table 5). The toxicity analysis of these inhibitors showed that there were no carcinogenic 
effect and organ toxicity. However, Rifampin, Tetrandrine and Fangchinoline were slightly positive 
in terms of mutagenesis though Azobechalcone and Isolophirachalcone inhibitors were completely 
negative. Among the top five inhibitors Azobechalcone was listed in the acute oral toxicity category 
2 and rest of them were listed in the category 3.  
 
4. Discussion 
Global pandemic caused by SARS-CoV-2 has become a major concern due to its excessive infection 
rate and lethality [51,52,53,54]. Despite huge research regarding the pathogen, no drugs or vaccine 
has proven satisfactory to combat infections caused by SARS-CoV-2 [55,56]. Several investigational 
drugs exist, however none of these could treat the patients unquestionably. Moreover, lack of rapid 
detection procedures made SARS-CoV-2 diagnosis troublesome [57]. Computational approach and 
drug repurposing strategies hold promise to face such challenges caused by SARS-CoV-2. Hence, in 
the present study, attempts were taken to suggest probable drug candidates by checking the efficacy 
of natural inhibitors to inhibit the key proteins of SARS-CoV-2. 
The race against the COVID-19 pandemic has allowed the drug repurposing through virtual for 
finding drugs that could be used for the treatment of COVID-19. Recent studies prioritized MPP 
inhibitors of SARS-CoV-2 i.e. alpha-ketoamide, Hydroxy, Remdesivir, Chloroquine and Favipiravir 
to evaluate their potency as drug [58,59,60]. Several in silico approach was also adopted to screen 
putative drug candidates against SARS-CoV-2 [61,62]. However, all these experiments used either 
main protease proteins or RNA-dependent RNA polymerase of SARS-CoV-2 as probable drug 
targets. In this study, we screened potential natural therapeutics against SARS-CoV-2 MPP, RdRp 
and spike protein by molecular docking approach. Here, Rifampin, Azobechalcone and  
Azobechalcone were determined as top most drug candidates as they interacted with SARS-CoV-2 
MPP, RdRp and spike protein with lowest negative binding energy had the highest negative binding 
energy (-16.3 kcal/mol, -15.9 kcal /mol and -14.4 kcal/mol respectively. However, comparative 
analysis revealed the superiority of 5 drug candidates i.e. Azobechalcone, Rifampin, 
Isolophirachalcone, Tetrandrine, Fangchinoline against SARS-CoV-2 (Table 4). The common drug 
surface hotspots were analyzed along with modeling of pharmacophore which is very important step 
for drug discovery. Three amino acid residues i.e. H41, C145, and M165 played the crucial role for 
the interaction of MPP with its inhibitors (i.e. Rifampin, Amentoflavone, Cepharanthine) (Table 1). 
Azobechalcone, the top scorer among RdRp inhibitors, Again, the position of F368, L371, L372, 
A375, W509, L514, Y515 were vital for binding of RdRP with Tetrandrine, Biflavone and 
Fangchinoline (Table 2). Most importantly, the binding patterns of spike protein with 
Isolophirachalcone, Fangchinoline and Tetrandrine were significantly similar. This study revealed 
the possibility of these amino acids to efficiently interact with drugs, though requires validation in 
wet lab trials. ADME analysis of top drug candidates reveled no undesirable consequences by these 
compounds. Various physico-chemical parameters, lipophilicity, pharmacokinetics properties and water 
solubility were determined (Table 5). In addition, no BBB permeant were identified among the top most 
inhibitors of MPP, RdRp and spike protein. The consequence of association of the natural inhibitory 
drugs of three key proteins with the cytochrome P450 (CYP) suggests that no substantial inhibition 
can occur. However, toxicity analysis revealed that Rifampin, Tetrandrine and Fangchinoline can be 
slightly mutagenic, though there was no possibility for organ toxicity. 
 
The results suggest that Azobechalcone, Rifampin, Isolophirachalcone and Tetrandrine, Fangchinoline 
could be an option to treat SARS-CoV-2 infections. However, the study employed various 
computational approaches to screen the potent natural therapeutics and does not involve in-vivo assay. 
Currently investigational drugs of SARS-CoV-2 are under immense experimental evaluation. 
Therefore, we suggest clinical trials for the experimental validation of our findings. 
 
Conclusion 
COVID-19 pandemic situation is going to be a worst condition throughout the world. Rapid detection 
and social distancing are being encouraged at this stage, but we need to search for immediate 
therapeutic options and effective vaccine candidates for battling this serious health crisis. Drug 
repurposing approaches could screened out the already approved drugs for reusing against any serious 
causative agents that are causing health complications. Plant metabolites based repurposed drug 
molecules could be a promising options against SARS-CoV-2. In the present study, five plantr based 
therapeutics such as Azobechalcone, Rifampin, Isolophirachalcone, Tetrandrine and Fangchinoline 
were suggested for potential inhibitors for the Main Protease protein, RNA dependent RNA 
polymerase and Spike protein of SARS-CoV-2 by using molecular docking based virtual screening 
study. The study initiated the window towards the thinking of plant based therapy against COVID-19, 
though extensive research and wet lab validation needs to make it usable for patient.  
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Table 1: Top screened plant metabolites against Main Protease Protein of SARS-CoV-2 
 
 
Table 2: Top screened plant metabolites against RdRp of SARS-CoV-2 
 
 
 
 
 
 
 
 
 
 
No Pub Chem ID Name 
Binding 
Energy 
(Kcal/mol) 
Involved Amino Acids 
1 135398735 Rifampin -16.3 
H41, N142, S144, C145, 
H163,M165, E166, D187, R188,  
Q189 
2 16148290  Azobechalcone -14.6 
R131, K137, T196, D197, T198, 
T199,  K236, Y237, N238, L272, 
G275, M276,  L286, L287 
3 101630349   Isolophirachalcone -13 
K137, D197, T199, Y237, N238, 
L271, L272, G275,  L286, L287, 
E288, D289, E290 
4 5281600 Amentoflavone -12.8 
H41, C145,  H164, M165, E166, 
D187, R188, Q189 
5 10206  Cepharanthine -12.7 
H41, N142, C145, M165, E166,  
D187, R188, Q189 
No 
Pub Chem 
ID 
Name 
Binding 
Energy 
(kcal/mol) 
Involved amino acids 
1 16148290  Azobechalcone -15.9 
Y32, K47, L49, Y129, 
H133, N138, D140, T141, 
S709, T710, D711, K714, 
K780, N781 
2 135398735 Rifampin -15.6 
L270, L271, Y273, T324, 
S325, F326, P328, A282, 
A283, F396, V398 
3 73078  Tetrandrine -13.9 
F368, L371, L372, A375, 
W509, Y515, S518 
4 9980790 Biflavone -13.7 
F368, L371, L372, A375, 
W509, L514, Y515 
5 73481  Fangchinoline -13.7 
F368, L371, L372, A375, 
W509, L514, Y515, S518 
Table 3: Top screened plant metabolites against Spike Protein of SARS-CoV-2 
 
 
 
 
 
 
 
 
 
Table 4: Top screened suggested plant metabolites against Main Protease, RdRpl and Spike Protein 
of SARS-CoV-2 for battling COVID-19 pandemic 
No Pub Chem ID Name 
Main 
Protease 
RdRpl 
Spike 
protein 
1 16148290  Azobechalcone -14.6 -15.9 -14.4 
2 135398735 Rifampin -16.3 -15.6 -13.7 
3 101630349   Isolophirachalcone -13 -13.3 -12.8 
4 73078  Tetrandrine -12.6 -13.9 -12.5 
5 73481  Fangchinoline -12.3 -13.7 -12.6 
 
 
 
 
 
 
No 
Pub Chem 
ID 
Name 
Binding 
Energy 
(kcal/mol) 
Involved Amino acid 
1 16148290  Azobechalcone -14.4 
L335, C336, F338, G339, F342, N343, 
V362, A363, D364, V367,L368,  S371, 
F374, W436, N437 
2 135398735 Rifampin -13.7 
P426, D428, T430, P463, F464, F515, 
E516, L517, L518 
3 101630349   Isolophirachalcone -12.8 
R355, Y396, P426, D428, F429, T430, 
K462, P463, F464, F515 
4 73481  Fangchinoline -12.6 
R355, Y396, P426, N428, P463, F464, 
S514, F515, E516 
5 73078  Tetrandrine -12.5 
R355, Y396, P426, N428,  P463, F464,  
S514, F515, E516 
Table 5: ADME analysis of top screened suggested plant metabolites against Main Protease, RdRpl 
and Spike Protein of SARS-CoV-2  
Parameter 
Name 
Azobechalc
one 
Rifampin 
Isolophirachal
cone 
Tetrandri
ne 
Fangchino
line 
PubChem ID 16148290 135398735 101630349   73078  73481  
Physicochem
ical 
parameters 
Formula 
C90H70O2
2 
C43H58N4
O12 
C60H48O15 
C38H42N
2O6 
C37H40N2
O6 
Molecular 
weight 
1503.51 
g/mol 
822.94 
g/mol 
1009.01 g/mol 
622.75 
g/mol 
608.72 
g/mol 
Molar 
Refractivity 
415.5 234.22 277.97 186.07 181.6 
TPSA 402.58 Å² 220.15 Å² 275.13 Å² 61.86 Å² 72.86 Å² 
Lipophilicity 
Log Po/w (iLO
GP) 
3.63 4.58 2.32 5.16 5.02 
Log Po/w (XLO
GP3) 
15.45 5.46 10.17 6.66 6.34 
Log Po/w (WLO
GP) 
14.52 3 9.48 5.75 5.45 
Log Po/w (MLO
GP) 
1.77 0.14 2.02 3.73 3.55 
Log Po/w (SILI
COS-IT) 
12.03 2.07 7.79 6.06 5.5 
Consensus 
Log Po/w 
9.48 3.05 6.36 5.47 5.17 
Pharmacokin
etics 
GI absorption Low Low Low High High 
BBB permeant No No No No No 
P-gp substrate Yes Yes Yes No No 
CYP1A2 
inhibitor 
No No No No No 
CYP2C19 
inhibitor 
No No No No No 
CYP2C9 
inhibitor 
No No No No No 
CYP2D6 
inhibitor 
No No No No No 
CYP3A4 
inhibitor 
No No No No No 
Log Kp (skin 
permeation) 
-4.50 cm/s -7.44 cm/s -5.23 cm/s -5.37 cm/s -5.51 cm/s 
Water 
Solubility 
Log S (SILICO
S-IT) 
-19.06 -4.74 -12.93 -10.8 -10.12 
Solubility 
1.30e-16 
mg/ml ; 
8.67e-20 
mol/l 
1.50e-02 
mg/ml ; 
1.83e-05 
mol/l 
1.18e-10 
mg/ml ; 1.17e-
13 mol/l 
9.78e-09 
mg/ml ; 
1.57e-11 
mol/l 
4.61e-08 
mg/ml ; 
7.57e-11 
mol/l 
Figure 1: Top screened plant metabolites for targeting the MPP, RdRp and S protein of SARS-CoV-2 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Molecular interaction of Rifampin with MPP of SARS-CoV-2 by molecular docking 
(Binding Energy -16.3 kcal/mol) 
 
Figure 3: Molecular interaction of Azobechalcone with RdRp of SARS-CoV-2 by molecular docking 
(Binding Energy -15.9 kcal/mol) 
 
 
Figure 4: Molecular interaction of Azobechalcone with S protein of SARS-CoV-2 by molecular 
docking (Binding Energy -14.4 kcal/mol) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1: Plant metabolites drug compounds retrieved from PubChem 
 No Name Pubchem ID Molecular 
formula 
1.  Betulinic Acid 64971 C30H48O3 
2.  Hinokinin 442879 C20H18O6 
3.  Savinin 5281867 C20H16O6 
4.  Curcumin 969516 IC21H20O6 
5.  Niclosamide 4477 C13H8Cl2N2O4 
6.  Atropine 174174 C17H23NO3 
7.  Biopterin 135449517 C9H11N5O3 
8.  Buchapine 461150 C19H23NO2 
9.  Camptothecin 24360 C20H16N2O4 
10.  Canavanin 439202 C5H12N4O3 
11.  Caffeine 2519 C8H10N4O2 
12.  Caribine 441590 C19H22N2O3 
13.  Carinatine 441591 C17H21NO4 
14.  Chelidonine 197810 C20H19NO5 
15.  Cordycepin 6303 C10H13N5O3 
16.  Cryptopleurine 92765 C24H27NO3 
17.  O-Demethyl-Buchenavianine 5352072 C21H21NO4 
18.  Emetine 10219   C29H40N2O4  
19.  Fagaronine 40305   C21H20NO4+ 
20.  Harmaline 3564   C13H14N2O   
21.  Harmine 5280953   C13H12N2O  
22.  Hypoxanthine 135398638   C5H4N4O  
23.  Lycorine 72378  C16H17NO4  
24.  Michellamines D 403970  
25.  Michellamines F 403969  
26.  10-Methoxycamptothecin 97283 C21H18N2O5 
27.  Odorinol 6440456 C18H24N2O3  
28.  Oliverine 24198103   C20H22ClNO4 
29.  Oxostephanine 343547   C18H11NO4 
30.  Pachystaudine 513596   C19H19NO4  
31.  Papaverine  4680  C20H21NO4 
32.  Psychotrine 65380   C28H36N2O4  
33.  Rifampin 135398735   C43H58N4O12 
34.  Schumannificine 184890    
35.  Solasonine 119247   C45H73NO16  
36.  Taspine 215159   C20H19NO6  
37.  Homonojirimycin 159496   C7H15NO5 
38.  Aranotin 10412012   C20H18N2O7S2  
39.  Gliotoxin 6223   C13H14N2O4S2  
40.  Ochropamine 134716677   C22H26N2O3 
 Name Pubchem ID Molecular 
formula 
41.  Epi-16-Ochropamine 6445875   C22H27ClN2O3  
42.  Glaucine Fumarate 16754   C21H25NO4 
43.  N-Methyllaurotetanine 16573   C20H23NO4  
44.  Isoboldine 133323   C19H21NO4  
45.  Nuciferine Hcl 53326062   C19H22ClNO2  
46.  Indigo 10215   C16H10N2O2 
47.  Sinigrin 23682211   C10H16KNO9S2   
48.  Aloeemodin 10207  C15H10O5  
49.  Hesperetin 72281   C16H14O6 
50.  Hirsutenone 637394   C19H20O5  
51.  Platyphyllenone 23786382   C19H20O3  
52.  Platyphyllone 13347313   C19H22O4 
53.  Platyphyllonol-5-
Xylopyranoside 
46230810   C24H30O8  
54.  Hirsutanonol 9928190   C19H22O6  
55.  Oregonin 14707658   C24H30O10  
56.  Rubranol 10088141  C19H24O5  
57.  Rubranoside B 24011643   C24H32O9  
58.  Rubranoside A 10097263   C25H34O10  
59.  Biflavone 9980790   C30H18O4  
60.  Amentoflavone 5281600   C30H18O10  
61.  Apigenin 5280443  C15H10O5  
62.  Luteolin 5280445   C15H10O6   
63.  Quercetin 5280343  C15H10O7  
64.  Tomentin A 71659627  C25H30O7 
65.  Tomentin B 71659628 C26H32O7 
66.  Tomentin C 71659765   C27H34O8  
67.  Tomentin D 71659766   C27H34O8  
68.  Tomentin E 71659767   C26H32O8 
69.  Chalcones D047188  
70.  Coumarins 54678486 C19H16O4 
71.  Herbacetin 5280544   C15H10O7   
72.  Rhoifolin 5282150   C27H30O14  
73.  Pectolinarin 168849   C29H34O15 
74.  Lycorine 72378   C16H17NO4  
75.  Tryptanthrin 73549   C15H8N2O2   
76.  Scutellarein  5281697 
 
C15H10O6  
77.  Myricetin 5281672   C15H10O8  
78.  Glycyrrhizin 14982   C42H62O16  
 
 
 No Name Pubchem ID Molecular 
formula 
79.  Herbacetin 5280544   C15H10O7  
80.  Quercetin 5280343   C15H10O7  
81.  Helichrysetin 6253344   C16H14O5  
82.  Tetrandrine  73078  C38H42N2O6  
83.  Fangchinoline 73481   C37H40N2O6  
84.  Cepharanthine 10206  C37H38N2O6  
85.  Rhoifolin 5282150   C27H30O14 
86.  Pectolinarin 168849   C29H34O15 
87.  Epigallocatechin 65064  C22H18O11  
88.  Gallocatechin Gallate 199472   C22H18O11  
89.  Emodin 3220   C15H10O5  
90.  Baicalin 64982   C21H18O11  
91.  Saikosaponins 107793   C42H68O13  
92.  Tetra-O-Galloyl-Β-D-
Glucose 
 471531   C34H28O22  
93.  Kaempferol 5280863   C15H10O6   
94.  Juglanin 5318717   C20H18O10  
95.  Tiliroside  5320686 C30H26O13 
96.  Afzelin 5316673   C21H20O10  
97.  Naringenin 932   C15H12O5 
98.  Genistein  5280961   C15H10O5  
99.  Castanospermine 54445   C8H15NO4  
100.  Australine  442628 C8H15NO4 
101.  Periformyline 11969538   C21H22N2O4  
102.  Perivine 6473766 C20H22N2O3  
103.  Vincaleucoblastine 241902   C46H60N4O13S  
104.  Columbamine 72310   C20H20NO4+ 
105.  Berberine 2353   C20H18NO4+  
106.  Palmitine 19009   C21H22NO4+  
107.  Narciclasine 72376   C14H13NO7 
108.  Lycoricidine  73065   C14H13NO6  
109.  Pancratistatin 441597   C14H15NO8 
110.  7-deoxypancratistatin 443741   C14H15NO7  
111.  Isonarciclasine 5479394   C14H13NO7 
112.  cis-Dihydronarciclasine 3000372   C14H15NO7  
113.  Pretazettine 73360   C18H21NO5  
114.  Buxamine E 442970   C26H44N2   
115.  Cyclobuxamine H 101281345   C24H42N2O  
116.  5-hydroxynoracronycine 5378702   C19H17NO4  
117.  Acrimarine F 5491701   C31H29NO8  
 Supplementary Table 2: Docking results of all plant metabolites drug compounds against three 
key proteins of SARS-CoV-2 
Pub Chem ID 
Binding energy 
against Main Protease 
(kcal/mol) 
Binding energy 
against RdRp 
(kcal/mol) 
Binding energy 
against Spike 
protein (kcal/mol) 
CID 16148290 -14.6 -15.9 -14.4 
CID 135398735 -16.3 -15.6 -13.7 
CID 101630349 -13 -13.3 -12.8 
CID 73481 -12.3 -13.7 -12.6 
CID 73078 -12.6 -13.9 -12.5 
CID 10206 -12.7 -13.5 -12.3 
CID 64971 -12.3 -13.1 -11.9 
CID 5281600 -12.8 -13.3 -11.6 
CID 9980790 -12.4 -13.7 -11.5 
CID 14982 -12.6 -13.6 -11.4 
CID 107793 -11.2 -12.4 -11.3 
CID 119247 -10.9 -12 -11.1 
CID 5281694 -11.6 -11.7 -11 
CID 5281599 -12.1 -12.1 -10.9 
CID 97283 -10.6 -10.2 -10.8 
CID 24360 -10.5 -10.4 -10.6 
CID 5480834 -12.1 -11.5 -10.5 
CID 5491701 -11.9 -11.8 -10.4 
CID 72412 -11.6 -12.1 -10.2 
CID 455249 -10.8 -12.1 -10.2 
CID 10412012 -11 -10.6 -10.1 
CID 102056152 -10.5 -11.5 -9.9 
CID 54675769 -10.4 -10.6 -9.9 
CID 5464386 -11.5 -11.6 -9.8 
CID 6473766 -10 -10.3 -9.8 
CID 168849 -10.2 -10.7 -9.7 
CID 168849 -10.6 -10.1 -9.7 
CID 11969538 -9.4 -9.9 -9.7 
CID 71659627 -9 -9.6 -9.7 
CID 442970 -9.8 -10.7 -9.5 
CID 5352072 -10.5 -10 -9.5 
CID 64982 -9.8 -9.9 -9.5 
CID 71659765 -9.1 -10.2 -9.3 
CID 54678486 -9.4 -9.8 -9.3 
CID 5281867 -8.6 -9.8 -9.3 
CID 442879 -8.9 -8.8 -9.3 
CID 101281345 -9.5 -10.7 -9.2 
CID 461150 -8.9 -9.7 -9.2 
CID 441590 -9.5 -9.4 -9.1 
CID 5282150 -9.9 -11.2 -9 
CID 442428 -9.9 -11.2 -9 
CID 5282150 -10.1 -11.1 -9 
CID 134716677 -9.5 -10.4 -9 
CID 71659628 -9 -9.7 -9 
CID 5316673 -10.3 -9.7 -8.9 
CID 5318717 -9.2 -9.7 -8.9 
CID 71659766 -8.2 -9.1 -8.9 
CID 5378702 -9 -9.8 -8.8 
CID 5280805 -11.5 -10.6 -8.7 
CID 5280804 -9.6 -9.9 -8.7 
CID  5320686 -8.5 -9.9 -8.6 
CID 122851 -10 -9.7 -8.6 
CID5280637 -9.7 -9.4 -8.6 
CID 199472 -9.2 -9.5 -8.5 
CID 65064 -9.2 -9.4 -8.5 
CID 6440456 -8.4 -9.4 -8.5 
CID 10219 -8.8 -9.1 -8.5 
CID 71659767 -8.6 -9 -8.5 
CID 14707658 -10.2 -9.7 -8.4 
CID 442882 -9.7 -9.7 -8.4 
CID 513596 -8.7 -9.2 -8.4 
CID 40305 -8.2 -9.1 -8.4 
CID 6445875 -8.3 -8.6 -8.4 
CID 73360 -8.6 -9 -8.3 
CID 72378 -8.6 -8.4 -8.3 
CID 471531 -11.1 -11 -8.2 
CID 184890 -9 -9.9 -8.2 
CID 65380 -9.2 -8.8 -8.2 
CID 5281697 -8.5 -8.7 -8.2 
CID 5281672 -8.2 -8.6 -8.2 
CID 73065 -8.2 -8.6 -8.2 
CID 2353 -8.5 -8.5 -8.2 
CID 24198103 -7.9 -8.4 -8.2 
CID 5479394 -8.7 -9.3 -8.1 
CID 443741 -8.5 -9.3 -8.1 
CID 40305 -8.2 -9.1 -8.1 
CID 343547 -9 -9 -8.1 
CID 439533 -8.1 -8.9 -8.1 
CID 10215 -8.1 -8.8 -8.1 
CID 72376 -8.7 -8.7 -8.1 
CID 5280343 -8.1 -8.7 -8.1 
CID 5280343 -8.1 -8.7 -8.1 
CID 3000372 -8.4 -8.6 -8.1 
CID 5281680 -8.3 -8.5 -8.1 
CID 5281614 -8.1 -8.3 -8.1 
CID 637394 -7.4 -7.8 -8.1 
CID 10088141 -7.4 -7.7 -8.1 
CID 92765 -8.8 -9.7 -8 
CID 441597 -8.6 -9.3 -8 
CID 3220 -8.6 -9.1 -8 
CID 73549 -8.1 -8.7 -8 
CID 72281 -8 -8.5 -8 
CID 6223 -8.5 -8.4 -8 
CID 5280445 -8.2 -8.3 -8 
CID 932 -8.2 -8.6 -7.9 
CID 5280443 -8.2 -8.6 -7.9 
CID 23786382 -7 -8.6 -7.9 
CID 24011643 -8.8 -8.5 -7.9 
CID 5281670 -8.2 -8.5 -7.9 
CID 5489090 -9.2 -8.3 -7.9 
CID 5280443 -8.2 -8.3 -7.9 
CID 9928190 -7.5 -8.3 -7.9 
CID 5317756 -8.5 -9.6 -7.8 
CID 10207 -8 -8.6 -7.8 
CID 5280681 -8.1 -8.4 -7.8 
CID 5280544 -8 -8.3 -7.8 
CID 5280544 -8 -8.3 -7.8 
CID 16573 -7.8 -8 -7.8 
CID 969516 -7.1 -6.9 -7.8 
CID 5280862 -8 -8.1 -7.7 
CID 5281603 -8.2 -8 -7.7 
CID 5280961 -8.1 -8 -7.7 
CID 5280863 -7.9 -8 -7.7 
CID 440832 -7.6 -7.9 -7.7 
CID 4477 -7.9 -7.4 -7.7 
CID 13347313 -7.1 -7.2 -7.7 
CID 441591 -8 -8.6 -7.6 
  
 
 
 
CID 10097263 -9 -8.4 -7.6 
CID 133323 -8.2 -8.4 -7.6 
CID 53326062 -6.9 -8.4 -7.6 
CID 5316900 -7.9 -8 -7.6 
CID 19009 -8.1 -7.9 -7.6 
CID 5281677 -8.1 -7.8 -7.6 
CID 5281677 -8.1 -7.8 -7.6 
CID 5280378 -7.6 -7.8 -7.6 
CID 44259819 -9 -8.8 -7.5 
CID 46230810 -6.8 -8.7 -7.4 
CID 197810 -8 -8.2 -7.4 
CID 189065 -8.1 -8.1 -7.4 
CID 72310 -7.9 -8 -7.3 
CID 72310 -7.9 -8 -7.3 
CID 5459184 -7.6 -7.8 -7.3 
CID 5281704 -7.8 -7.6 -7.3 
CID 16754 -7.9 -8.1 -7.2 
CID 6253344 -6.8 -7.4 -7.2 
CID 23682211 -7.5 -7.7 -7.1 
CID 215159 -7.8 -8 -7 
CID 4680 -7 -7.1 -7 
CID 5280953 -6.4 -6.7 -6.8 
CID 119586 -6.9 -7.4 -6.7 
CID 174174 -7 -6.8 -6.7 
CID 3564 -6.6 -7.5 -6.6 
CID 6303 -6.7 -7.1 -6.6 
CID 135449517 -6.5 -6.6 -6.6 
CID 5281541 -6.2 -6.7 -6.1 
CID 54445 -6.6 -7.1 -6 
CID 159496 -5.6 -7.1 -5.7 
CID 442628 -6 -6.4 -5.6 
CID 2519 -5.7 -6.1 -5.4 
CID 403969 -5.2 -5.8 -5.2 
CID 135398638 -5.7 -6 -4.9 
CID 439202 -5.1 -5.3 -4.9 
CID 241902 -3.8 -4.5 -3.4 
